CN113633677A - Mitochondrial nutrient composition for relieving sympathetic nerves and application - Google Patents
Mitochondrial nutrient composition for relieving sympathetic nerves and application Download PDFInfo
- Publication number
- CN113633677A CN113633677A CN202110950366.5A CN202110950366A CN113633677A CN 113633677 A CN113633677 A CN 113633677A CN 202110950366 A CN202110950366 A CN 202110950366A CN 113633677 A CN113633677 A CN 113633677A
- Authority
- CN
- China
- Prior art keywords
- weight
- parts
- sympathetic
- nutrient composition
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 48
- 230000002889 sympathetic effect Effects 0.000 title claims abstract description 43
- 230000002438 mitochondrial effect Effects 0.000 title claims abstract description 40
- 235000015097 nutrients Nutrition 0.000 title claims abstract description 38
- 210000005036 nerve Anatomy 0.000 title claims abstract description 30
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims abstract description 32
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 28
- 235000020230 cinnamon extract Nutrition 0.000 claims abstract description 18
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims abstract description 16
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 claims abstract description 16
- 229960001009 acetylcarnitine Drugs 0.000 claims abstract description 16
- 229960002685 biotin Drugs 0.000 claims abstract description 16
- 235000020958 biotin Nutrition 0.000 claims abstract description 16
- 239000011616 biotin Substances 0.000 claims abstract description 16
- 235000020221 chamomile extract Nutrition 0.000 claims abstract description 16
- 229940119217 chamomile extract Drugs 0.000 claims abstract description 16
- 235000017471 coenzyme Q10 Nutrition 0.000 claims abstract description 16
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims abstract description 16
- 229940110767 coenzyme Q10 Drugs 0.000 claims abstract description 16
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 claims abstract description 16
- 235000019136 lipoic acid Nutrition 0.000 claims abstract description 16
- 229960002663 thioctic acid Drugs 0.000 claims abstract description 16
- 235000017309 Hypericum perforatum Nutrition 0.000 claims abstract description 14
- 244000141009 Hypericum perforatum Species 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims description 13
- 238000009472 formulation Methods 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 239000008187 granular material Substances 0.000 claims description 8
- 239000002245 particle Substances 0.000 claims description 6
- 230000003938 response to stress Effects 0.000 claims description 6
- 235000013361 beverage Nutrition 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 230000002040 relaxant effect Effects 0.000 claims 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 12
- 206010022437 insomnia Diseases 0.000 description 12
- 230000000694 effects Effects 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 7
- 230000035882 stress Effects 0.000 description 7
- 208000019901 Anxiety disease Diseases 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 230000036506 anxiety Effects 0.000 description 4
- 230000037326 chronic stress Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 210000000653 nervous system Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 239000003125 aqueous solvent Substances 0.000 description 3
- 210000003403 autonomic nervous system Anatomy 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 231100000430 skin reaction Toxicity 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 2
- 206010040914 Skin reaction Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000000467 autonomic pathway Anatomy 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- IWBJJCOKGLUQIZ-HQKKAZOISA-N hyperforin Chemical compound OC1=C(CC=C(C)C)C(=O)[C@@]2(CC=C(C)C)C[C@H](CC=C(C)C)[C@](CCC=C(C)C)(C)[C@]1(C(=O)C(C)C)C2=O IWBJJCOKGLUQIZ-HQKKAZOISA-N 0.000 description 2
- QOVWXXKVLJOKNW-UHFFFAOYSA-N hyperforin Natural products CC(C)C(=O)C12CC(CC=C(C)C)(CC(CC=C(C)C)C1CCC=C(C)C)C(=C(CC=C(C)C)C2=O)O QOVWXXKVLJOKNW-UHFFFAOYSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000035483 skin reaction Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 210000002820 sympathetic nervous system Anatomy 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 240000003538 Chamaemelum nobile Species 0.000 description 1
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 241000218195 Lauraceae Species 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 1
- 206010049565 Muscle fatigue Diseases 0.000 description 1
- 206010049816 Muscle tightness Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 230000004094 calcium homeostasis Effects 0.000 description 1
- 230000003683 cardiac damage Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 229930004069 diterpene Natural products 0.000 description 1
- 150000004141 diterpene derivatives Chemical class 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000002567 electromyography Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000004129 fatty acid metabolism Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- -1 flavonoid compounds Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 230000009760 functional impairment Effects 0.000 description 1
- 230000000574 ganglionic effect Effects 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 210000001617 median nerve Anatomy 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000006676 mitochondrial damage Effects 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000008035 nerve activity Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 229940054010 other antipsychotics in atc Drugs 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 210000001002 parasympathetic nervous system Anatomy 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Anesthesiology (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to the technical field of foods and nutritional supplements, in particular to a mitochondrial nutrient composition for relieving sympathetic nerves and application thereof, wherein the mitochondrial nutrient composition comprises chamomile extract, cinnamon extract, coenzyme Q10, lipoic acid, acetyl carnitine, biotin and hypericum perforatum extract.
Description
[ technical field ] A method for producing a semiconductor device
The invention relates to the technical field of foods and nutritional supplements, in particular to a mitochondrial nutrient composition for relieving sympathetic nerves and application thereof.
[ background of the invention ]
The autonomic nervous system is a part of the nervous system that constitutes a nervous system that cannot be regulated by consciousness, and, unlike the somatic motor nervous system that mainly controls skeletal muscles, mainly innervates cardiac muscle, smooth muscle, and glandular tissue. The autonomic nervous system is also different from the motor nervous system in structure and is composed of pre-ganglionic neurons and post-ganglionic neurons, the autonomic nervous system is divided into a sympathetic nervous system and a parasympathetic nervous system, and the respective functions are different. The two resist each other and act synergistically, which plays an important role in maintaining the homeostasis of an organism.
Studies have shown that during stress, the sympathetic nervous system is activated. Stress is a phenomenon that the brain perceives as a dangerous or potentially dangerous condition that activates body resources. When the stress is too high, the body resources are in a load state, and the long-term severe stress (also called chronic stress) can damage the human body.
The sympathetic nerves innervating the adrenal glands are located in the hypothalamic pituitary kidney, from which the body's response to stress is controlled, which stimulates the release of steroid hormones as well as the release of dopamine, norepinephrine and epinephrine. During stress reactions, the brain, cardiovascular, immune, respiratory and digestive systems are affected. Stress responses are not activated purely by physical or physiological threats, but by individual anxiety, and the accumulation of minute and daily stress results in chronic stress; when the sympathetic nerves are damaged by the attack of the virus, the abnormal sympathetic nerves put the individual in a chronic stress state during the self-healing process. Chronic stress is mainly manifested as muscle tension, fatigue or insomnia.
Mitochondria are the "motor" part of the cell, and play a crucial role not only in the key organelles for intracellular energy production, but also in the regulation of many important physiological and biochemical processes, such as apoptosis, calcium homeostasis, oxidative stress, fatty acid metabolism, etc. Thus, mitochondrial failure or functional impairment leads to a variety of important diseases including neurodegenerative disorders, aging, obesity, tumors, heart and liver damage.
Mitochondrial nutrients are capable of repairing mitochondrial damage, inhibiting oxidant production in mitochondria, repairing oxidant damage, and acting as cofactors to protect the activity of mitochondrial enzymes and kinases. Mitochondrial nutrients are used in the fields of parkinson treatment, anti-fatigue and hypoglycemic treatment and the like in the prior art, and the prior art does not describe that the mitochondrial nutrients have a regulating effect on autonomic nerves.
[ summary of the invention ]
The invention aims to provide a mitochondrial nutrient composition for relieving sympathetic nerves and application thereof.
The technical scheme of the invention is as follows: a mitochondrial nutrient composition for soothing sympathetic nerves is provided, comprising chamomile extract, cinnamon extract, coenzyme Q10, lipoic acid, acetyl carnitine, biotin, and Hypericum perforatum extract.
Optionally, the feed comprises 20-30 parts by weight of chamomile extract, 20-30 parts by weight of cinnamon extract, 5-20 parts by weight of coenzyme Q10, 5-20 parts by weight of lipoic acid, 1-5 parts by weight of acetyl carnitine, 0.2-2 parts by weight of biotin and 10-20 parts by weight of hypericum perforatum extract.
The other technical scheme of the invention is as follows: a formulation of a mitochondrial nutrient composition for soothing sympathetic nerves is provided.
Optionally, the particle size of the preparation is smaller than or equal to a first particle size, and the first particle size is 10-80 meshes.
The other technical scheme of the invention is as follows: there is provided the use of a mitochondrial nutrient composition for soothing sympathetic nerves in the manufacture of a medicament or food or nutritional supplement for improving sympathetic stress response.
The other technical scheme of the invention is as follows: there is provided the use of a mitochondrial nutrient composition for soothing sympathetic nerves in the manufacture of a medicament or food or nutritional supplement for improving sleep.
The other technical scheme of the invention is as follows: there is provided the use of a formulation of a mitochondrial nutrient composition for soothing sympathetic nerves in the manufacture of a medicament or food or nutritional supplement for improving sympathetic stress response.
Optionally, the medicament or food or nutritional supplement is formulated into oral preparations, including any one of powder, tablet, granule, pill, emulsion, granule, capsule, solid beverage and gel soft candy.
The other technical scheme of the invention is as follows: there is provided the use of a formulation of a mitochondrial nutrient composition for soothing sympathetic nerves in the manufacture of a medicament or food or nutritional supplement for improving sleep.
Optionally, the medicament or food or nutritional supplement is formulated into oral preparations, including any one of powder, tablet, granule, pill, emulsion, granule, capsule, solid beverage and gel soft candy.
The mitochondrial nutrient composition for relieving sympathetic nerves comprises a chamomile extract, a cinnamon extract, coenzyme Q10, lipoic acid, acetyl carnitine, biotin and a hypericum perforatum extract, and can improve sympathetic nerve activity of insomnia people by matching mitochondrial nutrient components with sleep promoting components, and has the effect of regulating autonomic nerve functions of the insomnia people.
[ detailed description ] embodiments
The present invention will be further described with reference to the following embodiments.
The invention provides a mitochondrial nutrient composition for relieving sympathetic nerves, which comprises 20-30 parts by weight of chamomile extract, 20-30 parts by weight of cinnamon extract, 5-20 parts by weight of coenzyme Q10, 5-20 parts by weight of lipoic acid, 1-5 parts by weight of acetyl carnitine, 0.2-2 parts by weight of biotin and 10-20 parts by weight of hypericum perforatum extract.
In this example, coenzyme Q10, lipoic acid, acetyl carnitine and biotin were identified in the prior art as mitochondrial nutrients, chamomile extract and hypericum perforatum extract were considered to have a sleep-promoting and anxiety-relieving effect, and cinnamon extract was not directly proven to have a sleep-promoting and anxiety-relieving effect but was applied to be compatible with the main ingredient in the sleep-promoting composition. In this example, the combination of mitochondrial nutrient components and sleep-promoting components provides a sympathetic nerve modulation effect.
Research shows that one of reasons for causing insomnia and anxiety is low brain energy level, so exogenous supplement of mitochondrial nutrient coenzyme Q10, lipoic acid, acetyl carnitine and biotin can improve the brain energy level, further relieve anxiety and improve insomnia; flos Matricariae Chamomillae extract and herba Hyperici perforati extract have effects of promoting sleep, relieving anxiety, and eliminating stress; the effective components of the cinnamon extract comprise volatile oil, diterpene and glucoside thereof, flavonoid compounds and other components, have the effects of relieving physical fatigue and the like, and are also widely applied to the sleep-promoting composition. The composition can relieve sympathetic nerves by the compatibility and the synergistic effect of different components, and has a remarkable effect on improving insomnia.
In this embodiment, the chamomile extract may be prepared from fresh plant components selected from one or more of the group consisting of leaves, stems, roots, inflorescences, in combination. In particular, one or more leaches of fresh plant components may be performed using appropriate volumes of organic or aqueous organic or other aqueous solvents. The organic solvent used includes but is not limited to n-hexane, edible alcohol, methanol, isopropanol, ethyl acetate and mixtures thereof; the aqueous organic solvent is selected from ethanol, methanol, isopropanol, and mixed solvent of acetic acid and water; the aqueous solvent comprises a mixture of water and at least one of an inorganic acid or base, either alone or in combination with one or more of the selected organic solvents. If no heating is applied during the soaking process, the mixture of the aqueous solvent and the botanical component can be heated above boiling for 15 minutes to 2 hours to produce a chamomile extract.
In this example, the cinnamon extract is prepared from the bark of cinnamon belonging to the family lauraceae. Specifically, the main production process flow of the cinnamon extract comprises the following steps: decocting → percolating → refluxing → distilling → precipitating → standing → filtering → concentrating → drying, the content of effective component of the extract is 15%.
In this example, the hyperforin perforatum extract is prepared by refluxing with ethanol to obtain an extract, eluting with macroporous resin, extracting with ethyl acetate, and drying to obtain the hyperforin perforatum extract.
Example 1
This example provides a mitochondrial nutrient composition for soothing sympathetic nerves comprising 20 parts by weight of chamomile extract, 20 parts by weight of cinnamon extract, 20 parts by weight of coenzyme Q10, 20 parts by weight of lipoic acid, 1 part by weight of acetyl-carnitine, 0.2 part by weight of biotin, and 15 parts by weight of hypericum perforatum extract.
Example 2
This example provides a mitochondrial nutrient composition for soothing sympathetic nerves comprising 20 parts by weight of chamomile extract, 20 parts by weight of cinnamon extract, 20 parts by weight of coenzyme Q10, 5 parts by weight of lipoic acid, 1 part by weight of acetyl-carnitine, 1 part by weight of biotin and 10 parts by weight of hypericum perforatum extract.
Example 3
This example provides a mitochondrial nutrient composition for soothing sympathetic nerves comprising 20 parts by weight of chamomile extract, 20 parts by weight of cinnamon extract, 5 parts by weight of coenzyme Q10, 20 parts by weight of lipoic acid, 5 parts by weight of acetyl carnitine, 1 part by weight of biotin and 20 parts by weight of hypericum perforatum extract.
Example 4
This example provides a mitochondrial nutrient composition for soothing sympathetic nerves comprising 20 parts by weight of chamomile extract, 25 parts by weight of cinnamon extract, 10 parts by weight of coenzyme Q10, 15 parts by weight of lipoic acid, 3 parts by weight of acetyl-carnitine, 2 parts by weight of biotin and 15 parts by weight of hypericum perforatum extract.
Example 5
The present example provides a mitochondrial nutrient composition for soothing sympathetic nerves, including 30 parts by weight of chamomile extract, 30 parts by weight of cinnamon extract, 20 parts by weight of coenzyme Q10, 15 parts by weight of lipoic acid, 4 parts by weight of acetyl-carnitine, 1 part by weight of biotin, and 10 parts by weight of hypericum perforatum extract.
Example 6
This example provides a mitochondrial nutrient composition for soothing sympathetic nerves comprising 25 parts by weight of chamomile extract, 30 parts by weight of cinnamon extract, 15 parts by weight of coenzyme Q10, 15 parts by weight of lipoic acid, 5 parts by weight of acetyl carnitine, 1 part by weight of biotin and 10 parts by weight of hypericum perforatum extract.
Comparative example 1
This example provides a mitochondrial nutrient composition for soothing sympathetic nerves comprising 20 parts by weight of coenzyme Q10, 20 parts by weight of lipoic acid, 5 parts by weight of acetyl carnitine, and 2 parts by weight of biotin.
Comparative example 2
This example provides a sympathetically soothing composition comprising 20 parts by weight of an extract of chamomile.
Comparative example 3
The present example provides a sympathetic soothing composition comprising 20 parts by weight of cinnamon extract.
Examples and comparative sympathetic skin response detection
The compositions of examples 1 to 3 and comparative examples 1 to 3 were each prepared into a granular formulation.
56 insomnia volunteers of 25-60 years old and 8 healthy volunteers, both male and female, were recruited socially. The selection criteria of the insomnia volunteers are as follows: the diagnosis standard of insomnia in Chinese mental disorder classification and diagnosis standard (3 rd edition, CCMD-3) is met; no medications to improve sleep or other antipsychotics; ③ non-progressive central nervous system diseases and other systemic diseases. The insomnia volunteers were divided into 7 groups of 8 persons each, half of both male and female. 7 groups of insomnia volunteers were divided into a blank group, an example group and a comparative example group and intervened according to the table 1, and the 7 groups were all taken 3 times/day with 1g of dosage each time and taken 1h after meals for 30 days continuously. After 30 days, sympathetic nerve skin reaction (SSR) detection was performed together with healthy volunteers as a control group.
TABLE 1 volunteer group intervention scenarios
SSR was measured in 8 groups of volunteers by a neuroExam M-800A electromyogram/evoked potential instrument (Zhuhaimaikang technology). Resting for 30min before detection, wherein the detection environment is a quiet shielding room, the subject keeps clear and relaxes the supine position, and the room temperature is controlled to be 22-26 ℃. Recording electrodes are placed on the palm side of the hand and the foot, reference electrodes are placed on the back side of the hand and the foot, and the current stimulates the median nerve of the wrist. The stimulation duration is 0.2ms, the band pass is 1.0-40HZ, the analysis time is 3s, the stimulation current is 11.8-30.2 mA, the obvious contraction of the muscle of the big fish is taken as a standard, and the interval is 30 s. Each example was repeated 4 times, and the SSR onset latency and wave amplitude were measured and averaged 4 times. Judging standard of abnormal SSR: 1. SSR loss of one or more limbs; 2. the incubation period is prolonged; 3. the amplitude is reduced. Any one of the three abnormalities is abnormal SSR. The normal value range refers to the 'concise electromyography handbook' of 2006 science publishers. The results are shown in Table 2. The incubation period of the blank group SSR is obviously prolonged compared with the control group, and the amplitude of the blank group SSR is obviously reduced compared with the control group; the incubation period of the SSRs in the example group is obviously shortened compared with that in the blank group, and the amplitude of the SSRs in the example group is obviously increased compared with that in the blank group; compared with the example group, the incubation period of the comparative example group is far shorter than that of the example group; the amplitude increase was not as significant as the group of examples. The composition has obvious improvement effect on sympathetic nerves; secondly, compared with the single sleep promoting component, the combination of the mitochondrial nutrient component and the sleep promoting component can better improve the sympathetic nerve skin reaction of insomnia people, and the mitochondrial nutrient component and the sleep promoting component generate synergistic effect.
SSR latency and amplitude contrast analysis of group of people in Table 28
While the foregoing is directed to embodiments of the present invention, it will be understood by those skilled in the art that various changes may be made without departing from the spirit and scope of the invention.
Claims (10)
1. A mitochondrial nutrient composition for soothing sympathetic nerves, comprising chamomile extract, cinnamon extract, coenzyme Q10, lipoic acid, acetyl carnitine, biotin, and Hypericum perforatum extract.
2. The sympathetic nerve soothing mitochondrial nutrient composition of claim 1, comprising 20-30 parts by weight of chamomile extract, 20-30 parts by weight of cinnamon extract, 5-20 parts by weight of coenzyme Q10, 5-20 parts by weight of lipoic acid, 1-5 parts by weight of acetyl carnitine, 0.2-2 parts by weight of biotin and 10-20 parts by weight of hypericum perforatum extract.
3. A formulation of a sympathetic soothing mitochondrial nutrient composition of claim 1 or 2.
4. A preparation of sympathetic relaxing mitochondrial nutrient composition according to claim 3 wherein the particle size of the preparation is less than or equal to a first particle size, the first particle size being 10-80 mesh.
5. Use of a sympathetic soothing mitochondrial nutrient composition according to claim 1 or 2 for the preparation of a medicament or food or nutritional supplement for improving sympathetic stress response.
6. Use of a sympathetic soothing mitochondrial nutrient composition according to claim 1 or 2 for the preparation of a medicament or food or nutritional supplement for improving sleep.
7. Use of a formulation of sympathetic soothing mitochondrial nutrient composition according to claim 3 or 4 for the preparation of a medicament or food or nutritional supplement for improving sympathetic stress response.
8. The use according to claim 7, wherein the medicament or food or nutritional supplement is formulated into an oral formulation comprising any one of powder, tablet, granule, pill, emulsion, granule, capsule, solid beverage and gel-fondant.
9. Use of a formulation of sympathetic soothing mitochondrial nutrient composition according to claim 3 or 4 for the preparation of a medicament or food or nutritional supplement for improving sleep.
10. The use according to claim 9, wherein the medicament or food or nutritional supplement is formulated into an oral formulation comprising any one of powder, tablet, granule, pill, emulsion, granule, capsule, solid beverage and gel-fondant.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110950366.5A CN113633677B (en) | 2021-08-18 | 2021-08-18 | Mitochondrial nutrient composition for improving sleep and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110950366.5A CN113633677B (en) | 2021-08-18 | 2021-08-18 | Mitochondrial nutrient composition for improving sleep and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113633677A true CN113633677A (en) | 2021-11-12 |
| CN113633677B CN113633677B (en) | 2022-10-21 |
Family
ID=78422753
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110950366.5A Active CN113633677B (en) | 2021-08-18 | 2021-08-18 | Mitochondrial nutrient composition for improving sleep and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113633677B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060257502A1 (en) * | 2005-05-11 | 2006-11-16 | Jiankang Liu | A combination of mitochondrial nutrients for relieving stress, preventing and improving stress-related disorders |
| CN101045048A (en) * | 2006-03-27 | 2007-10-03 | 中国科学院上海生命科学研究院 | Application of chondriosome nutrient composition for preventing and treating insulin resistance and biabetes |
-
2021
- 2021-08-18 CN CN202110950366.5A patent/CN113633677B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060257502A1 (en) * | 2005-05-11 | 2006-11-16 | Jiankang Liu | A combination of mitochondrial nutrients for relieving stress, preventing and improving stress-related disorders |
| CN101045048A (en) * | 2006-03-27 | 2007-10-03 | 中国科学院上海生命科学研究院 | Application of chondriosome nutrient composition for preventing and treating insulin resistance and biabetes |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113633677B (en) | 2022-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Umadevi et al. | Traditional and medicinal uses of Withania somnifera | |
| CN103859379A (en) | Formula and preparation method of life cultivation and health preservation food helpful for improving memory | |
| KR101826737B1 (en) | A composition containing herbs extract, and manufacturing method of the same | |
| CN105708970B (en) | A kind of health food with function of blood sugar reduction | |
| CN107751993A (en) | A kind of antifatigue cream taste and preparation method thereof | |
| CN108813501B (en) | Health-preserving honey paste with functions of clearing heat, moistening lung, relieving cough, reducing phlegm, relieving asthma and regulating human body functions | |
| KR20090021644A (en) | A carbohydrate and lipid absorption inhibitory nelumbo composition and its manufacturing process thereof | |
| CN103142916B (en) | Medicament for preventing and treating senile dementia and preparation method thereof | |
| CN113633677B (en) | Mitochondrial nutrient composition for improving sleep and application | |
| KR20180126231A (en) | A composition comprising herbal mixture extract for neuroprotection | |
| CN106962910B (en) | Health-care composition for reducing blood pressure | |
| CN110960632B (en) | Formula of sleep improving product and preparation method thereof | |
| CN1233337C (en) | Medicine for treating Parkinson's disease and its preparing process | |
| CN113018398A (en) | Anti-fatigue health product and preparation method thereof | |
| KR20130088783A (en) | Compositions for preventing or treating multiple sclerosis | |
| CN108813500B (en) | Health-preserving honey paste with effects of tonifying middle-jiao and Qi, nourishing blood and soothing nerves and regulating human body functions | |
| CN103127255B (en) | Antioxidant externally-applied Chinese medicine dressing formula for treating asthma and preparation method thereof | |
| US20180000881A1 (en) | Phosphatidylserine-Containing Diet Supplement Aids With Melatonin Anti-Catabolic Dietary Nutrients | |
| CN102308989B (en) | Health care composition of formica rufa, grape and propolis extracts | |
| CN112057525A (en) | Miao medicine for regulating hypertension, hyperglycemia and hyperlipidemia and preparation process thereof | |
| Pal et al. | Therapeutic uses of Withania somnifera (Ashwagandha) | |
| CN115414448B (en) | Traditional Chinese medicine composition with neuroprotection effect, preparation method and application | |
| KR102319382B1 (en) | For antioxidant, antidepressant and antistress compositions comprising boswellia | |
| TW201806612A (en) | Use of anisomeles indica in manufacture of medicament for anti-fatigue | |
| KR20090056640A (en) | Remedy for healing mental depression and manufacturing method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |